Swedish Orphan Biovitrum Overview

  • Founded
  • 2001

Founded
  • Status
  • Public

  • Employees
  • 1,555

Employees
  • Stock Symbol
  • SOBI

Stock Symbol
  • Investments
  • 7

  • Share Price
  • $21.42

  • (As of Wednesday Closing)

Swedish Orphan Biovitrum General Information

Description

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition). In 2020, new collaborations brought rights to gout drug pegadricase and complement-mediated disease drug Aspaveli.

Contact Information

Website
www.sobi.com
Formerly Known As
Biovitrum
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • Tomtebodavägen 23A
  • Solna
  • 112 76 Stockholm
  • Sweden
+46 08-697 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Swedish Orphan Biovitrum Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$21.42 $20.75 $17.63 - $26.03 $6.14B 296M 394K $1.06

Swedish Orphan Biovitrum Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 6,647,624 7,343,046 7,437,000 5,675,997
Revenue 1,830,448 1,808,250 1,655,156 1,506,387
EBITDA 596,633 666,057 725,900 641,970
Net Income 257,872 311,952 351,942 349,319
Total Assets 4,569,798 5,377,019 5,885,960 4,883,397
Total Debt 913,637 1,205,108 1,776,284 1,771,191
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Swedish Orphan Biovitrum Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Swedish Orphan Biovitrum‘s full profile, request access.

Request a free trial

Swedish Orphan Biovitrum Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started w
Drug Discovery
Stockholm, Sweden
1,555 As of 2022
000.00
0.000 0000-00-00
000000000000

000000

te velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000

000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000 000000000
Cambridge, MA
0000 As of 0000
00.00
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Swedish Orphan Biovitrum Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
000 000000 00000 Private Debt Financed Bresso, Italy 0000 000.00 000000000 000.00
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
You’re viewing 5 of 15 competitors. Get the full list »

Swedish Orphan Biovitrum Patents

Swedish Orphan Biovitrum Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3741867-A1 Sulfatase activity assay Inactive 24-May-2019 00000000 0
US-20200306138-A1 Syringe assembly with ion-exchange material Pending 17-Nov-2017 00000000 0
AU-2018368574-A1 Syringe assembly with ion-exchange material Pending 17-Nov-2017 00000000
CA-3082264-A1 Syringe assembly with ion-exchange material Pending 17-Nov-2017 00000000
EP-3710084-A1 Syringe assembly with ion-exchange material Pending 17-Nov-2017 A61M5/19
To view Swedish Orphan Biovitrum’s complete patent history, request access »

Swedish Orphan Biovitrum Executive Team (34)

Name Title Board Seat Contact Info
Guido Oelkers Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Daniel Rankin Head of Global Product and Portfolio Strategy (GPPS), Member of the Executive Committee
Paula Treutiger Vice President & Global Head of Communications
Anders Ullman Ph.D Chief Medical Officer & Head of Research
You’re viewing 5 of 34 executive team members. Get the full list »

Swedish Orphan Biovitrum Board Members (7)

Name Representing Role Since
Annette Clancy Self Board Member 000 0000
Håkan Björklund Ph.D Swedish Orphan Biovitrum Chairman 000 0000
Helena Saxon Self Board Member 000 0000
Pia Axelson Swedish Orphan Biovitrum Board Member 000 0000
You’re viewing 4 of 7 board members. Get the full list »

Swedish Orphan Biovitrum Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Swedish Orphan Biovitrum Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Swedish Orphan Biovitrum‘s full profile, request access.

Request a free trial

Swedish Orphan Biovitrum Investments & Acquisitions (7)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 11-Jun-2020 0000 0000 Drug Discovery 00000 000
0000 00000000 12-Nov-2019 0000000000 00000 Pharmaceuticals 00000 000
000000000 (00 18-Jul-2019 000000000 00000 Buildings and Property 00000 000
0000000 (0.0. 24-Jan-2019 000000000 00.000 Buildings and Property 00000 000
Amgen (Rights to Kineret - Anakinra) 09-Sep-2013 Corporate Asset Purchase Buildings and Property 00000000
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Swedish Orphan Biovitrum Subsidiaries (1)

Company Name Industry Location Founded
000000000 Drug Discovery Stockholm, Sweden 0000
To view Swedish Orphan Biovitrum’s complete subsidiaries history, request access »